Could a daily pill boost blood counts in aplastic anemia?
NCT ID NCT01328587
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug eltrombopag in 34 people with moderate aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Eltrombopag is a pill that mimics a natural protein to stimulate blood cell production. Researchers measured whether it safely improved platelet and red blood cell counts over 16-20 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eltrombopag
- What this could lead to
- If successful, eltrombopag could offer a new oral treatment option to improve blood cell counts and reduce transfusion needs in moderate aplastic anemia.
- What could go wrong
- This is a small, early-phase pilot study with only 34 participants. Results may not apply to all patients, and side effects or lack of response are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States